Canaccord raised the firm’s price target on Tandem Diabetes (TNDM) to $59 from $58 and keeps a Buy rating on the shares. The firm said they delivered a good Q1, reaffirmed its guidance, and shares still trades at a very attractive valuation with multiple catalysts; a product pipeline, the T2D opportunity, and financial inflection point.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strong Performance, Promising Outlook, and Buy Rating Affirmed by William Plovanic
- Tandem Diabetes price target lowered to $30 from $36 at Piper Sandler
- Tandem Diabetes price target lowered to $20 from $22 at Wells Fargo
- Tandem Diabetes Care: Strong Q1 Performance Amid Cautious Outlook and Hold Rating
- Tandem Diabetes Care Reports Record Q1 Sales Growth